Literature DB >> 20592355

Insulin-like growth factor-1 receptor (IGF-1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy.

Reinhard E Friedrich1, Christian Hagel, Sylva Bartel-Friedrich.   

Abstract

BACKGROUND: Insulin-like growth-factor 1 receptor (IGF-1R) plays a key role in the development of cancer and is important for the regulation of tissue growth, predominantly via the growth hormone (GH). Targeting IGF-1R is a current topic of cancer research. The aim of this study was to identify IGF-1R in undifferentiated carcinomas of the head and neck. PATIENTS AND METHODS: Twenty-one formalin-fixed and paraffin-embedded specimens from 20 patients with undifferentiated carcinomas were investigated. IGF-1R was detected immunohistochemically. In some cases, the infection status for Einstein Barr virus (EBV, DNA) or HPV (RNA) was known.
RESULTS: IGF-1R was detected in all tumours, regardless of differentiation or proof of EBV or HPV integration into the genome. DISCUSSION: This study revealed a broad expression of IGF-1R in undifferentiated carcinomas of the oropharyngeal and nasopharyngeal region, both in primaries and regional lymph nodes. These results suggest that IGF-1R expression in these tumours is capable of transmitting mitogenic signals to the neoplastic cells. The presence of IGF-1R in undifferentiated carcinomas suggests that these tumours can respond to IGF. Targeting this receptor may be a promising tool for the treatment of advanced stage NPC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20592355

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

Review 2.  Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer.

Authors:  A D Karatzanis; E Koudounarakis; I Papadakis; G Velegrakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-21       Impact factor: 2.503

3.  Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.

Authors:  Zujian Chen; Yi Jin; Dongsheng Yu; Anxun Wang; Ishrat Mahjabeen; Cheng Wang; Xiqiang Liu; Xiaofeng Zhou
Journal:  Oral Oncol       Date:  2012-03-17       Impact factor: 5.337

4.  A pilot study evaluating genetic alterations that drive tobacco- and betel quid-associated oral cancer in Northeast India.

Authors:  Dhirendra Singh Yadav; Indranil Chattopadhyay; Anand Verma; Thoudam Regina Devi; L C Singh; Jagannath Dev Sharma; Amal Ch Kataki; Sunita Saxena; Sujala Kapur
Journal:  Tumour Biol       Date:  2014-06-19

5.  LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation.

Authors:  Kathryn Tworkoski; Nancy Raab-Traub
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

Review 6.  The Regulation of Lymph Node Pre-Metastatic Niche Formation in Head and Neck Squamous Cell Carcinoma.

Authors:  Chen Hu; Qiang Huang; Qing Sun
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

7.  Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.

Authors:  Lisa A Elferink; Vicente A Resto
Journal:  J Signal Transduct       Date:  2011-06-07

Review 8.  IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review).

Authors:  Julia Durzyńska
Journal:  Oncol Rep       Date:  2014-09-19       Impact factor: 3.906

9.  Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer.

Authors:  Giannis Mountzios; Ioannis Kostopoulos; Vassiliki Kotoula; Ioanna Sfakianaki; Elena Fountzilas; Konstantinos Markou; Ilias Karasmanis; Sofia Leva; Nikolaos Angouridakis; Konstantinos Vlachtsis; Angelos Nikolaou; Ioannis Konstantinidis; George Fountzilas
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.